This is a comprehensive PG-level answer on Diabetes in Pregnancy drawn from Creasy & Resnik's Maternal-Fetal Medicine (9th ed.), Harrison's Principles of Internal Medicine (22nd ed., 2025), Tintinalli's Emergency Medicine, and updated with 2023-2026 PubMed evidence. Here's a summary of what's covered:
What's Included
1. Classification - White Classification + GDM vs PGDM distinction
2. Pathophysiology - Normal pregnancy insulin resistance, Pedersen hypothesis, beta-cell compensation failure in GDM, placental anti-insulin hormones
3. Risk Factors - Complete table including GCK-MODY
4. Screening & Diagnosis - Full flowchart covering:
- Two-step method (ACOG standard, USA) - 50g GCT → 100g 3-hr OGTT
- One-step method (IADPSG/WHO) - 75g 2-hr OGTT
- Exact diagnostic thresholds with tables (Carpenter-Coustan vs IADPSG)
- The HAPO study basis and the ongoing controversy
5. Maternal Complications - Retinopathy, nephropathy, DKA in pregnancy (with special features - occurs at lower glucose thresholds)
6. Fetal/Neonatal Complications - Macrosomia, shoulder dystocia, congenital malformations (PGDM only), RDS, neonatal hypoglycemia, caudal regression, GCK-MODY-related IUGR
7. Preconception Counseling - HbA1c targets, folic acid dosing, drug switches
8. Antenatal Management Flowchart - MNT, insulin dosing by trimester, oral agent comparison (metformin vs glyburide), CGM
9. Fetal Surveillance Flowchart - Anomaly scan, fetal echo, NST/BPP, delivery thresholds
10. Intrapartum & Delivery - Timing by condition, C/S indications (EFW ≥4500g), glucose targets during labor
11. Postpartum Management - Mandatory 75g OGTT at 4-12 weeks, long-term T2DM risk (7-10x), metformin prevention
12. Recent Evidence (2023-2026) - NEJM trial on early GDM treatment, Lancet 2024 epidemiology update, BMJ 2026 lifestyle intervention meta-analysis